JP2012517241A5 - - Google Patents

Download PDF

Info

Publication number
JP2012517241A5
JP2012517241A5 JP2011550213A JP2011550213A JP2012517241A5 JP 2012517241 A5 JP2012517241 A5 JP 2012517241A5 JP 2011550213 A JP2011550213 A JP 2011550213A JP 2011550213 A JP2011550213 A JP 2011550213A JP 2012517241 A5 JP2012517241 A5 JP 2012517241A5
Authority
JP
Japan
Prior art keywords
sample
bcl
gene
patient
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011550213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517241A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/023818 external-priority patent/WO2010093742A1/en
Publication of JP2012517241A publication Critical patent/JP2012517241A/ja
Publication of JP2012517241A5 publication Critical patent/JP2012517241A5/ja
Pending legal-status Critical Current

Links

JP2011550213A 2009-02-11 2010-02-11 Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 Pending JP2012517241A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15174909P 2009-02-11 2009-02-11
US61/151,749 2009-02-11
PCT/US2010/023818 WO2010093742A1 (en) 2009-02-11 2010-02-11 Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015162761A Division JP2016047044A (ja) 2009-02-11 2015-08-20 Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2012517241A JP2012517241A (ja) 2012-08-02
JP2012517241A5 true JP2012517241A5 (https=) 2013-03-28

Family

ID=42112120

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011550213A Pending JP2012517241A (ja) 2009-02-11 2010-02-11 Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
JP2015162761A Pending JP2016047044A (ja) 2009-02-11 2015-08-20 Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015162761A Pending JP2016047044A (ja) 2009-02-11 2015-08-20 Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物

Country Status (7)

Country Link
US (2) US9045800B2 (https=)
EP (1) EP2396427A1 (https=)
JP (2) JP2012517241A (https=)
CN (1) CN102388151A (https=)
CA (1) CA2751293A1 (https=)
MX (1) MX2011008488A (https=)
WO (1) WO2010093742A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150301053A1 (en) * 2012-05-10 2015-10-22 Eutropics Pharmaceuticals, Inc. Surrogate functional diagnostics test for cancer
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ, インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー, インコーポレイテッド がんの処置のための併用療法
US10829488B2 (en) 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
BR112020018978A2 (pt) 2018-07-31 2021-03-02 Ascentage Pharma (Suzhou) Co., Ltd. produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
EP3758005A1 (en) * 2019-06-24 2020-12-30 Koninklijke Philips N.V. Identification of the cellular function of an active nfkb pathway
WO2025136456A1 (en) * 2023-07-14 2025-06-26 Eil Therapeutics, Inc. Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5756696A (en) * 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) * 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5491224A (en) * 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5424414A (en) 1991-12-17 1995-06-13 Abbott Laboratories Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
US5464746A (en) 1991-12-17 1995-11-07 Abbott Laboratories Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7723099B2 (en) * 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
CN1834261A (zh) * 2005-11-15 2006-09-20 北京博奥生物芯片有限责任公司 基因分型芯片及其制备方法与应用
US20080233567A1 (en) * 2006-09-05 2008-09-25 Murray William E Companion diagnostic assays for cancer therapy
WO2008082643A2 (en) * 2006-12-28 2008-07-10 Abbott Laboratories Companion diagnostic assays for cancer therapy
CN102203788B (zh) * 2008-10-31 2015-05-20 Abbvie公司 用于装配成小组的癌细胞系以用于测试一种或多种药物组合物的功效的方法
JP6812855B2 (ja) 2017-03-10 2021-01-13 Jnc株式会社 ジアルキルアミノシランの製造方法

Similar Documents

Publication Publication Date Title
JP2012517241A5 (https=)
JP2013500001A5 (https=)
CN111662982B (zh) 用于脑胶质瘤早期诊断和/或复发监测的生物标志物及其应用
RU2014120427A (ru) Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака
CN102333887B (zh) 用于检测gi癌转移的方法
JP2014509515A5 (https=)
EP2036987A1 (en) Molecular markers for tumor cell content in tissue samples
EP3186394A1 (en) Treatment and detection of melanoma
TWI682034B (zh) 用於評估子宮內膜癌的發展風險或診斷子宮內膜癌的方法
TWI571514B (zh) 評估罹患大腸直腸癌風險的方法
CN114032308A (zh) Fam83a、kpna2、krt6a和ldha联合作为肺腺癌生物标志物的用途
CN110592223B (zh) 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用
CN111315897B (zh) 用于黑素瘤检测的方法
KR102241455B1 (ko) 조기 간암 진단을 위한 엑소좀 유래 microRNA 바이오마커 및 그 용도
CN112813167B (zh) 标志物linc01977及其应用
CN110577999A (zh) 一种cxcr4作为胃癌预后评估生物标志物的应用及诊断试剂盒
CN116287180A (zh) 检测标志物的试剂在制备用于诊断哮喘的试剂盒中的应用
CN118922561A (zh) 肾癌诊断用尿液miRNA标志物、诊断试剂及试剂盒
EP2716767A1 (en) Method for determining the prognosis of pancreatic cancer
US20150087549A1 (en) Methods of using tissue biomarkers for indication of progression from barretts esophagus to esophageal adenocarcinoma
US20120149027A1 (en) Method for Determining the Risk of Metastasis as an Indicator for Diagnostic Imaging
ES2856232A1 (es) Biomarcadores para predecir la respuesta de un sujeto a una terapia con bcg, metodos y usos basados en los mismos
CN120230852A (zh) 一种基于miR-21的3’末端2’-O-甲基化作为肺癌诊断标记物的用途及应用
AU2024237081A1 (en) Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods
CN119570928A (zh) 用于结直肠癌诊断和预后预测的lncRNA组合